MLTX Research and Charts

MLTX - MoonLake Immunotherapeutics Class A (Healthcare: Biotechnology)

Projected Earnings Date: 2026-02-04 (Delayed quote data 2026-02-10)

Last 15.62	Change ⇓ -0.13 (-0.83%)	Volume 782,815
	Open 15.79	High 16.15	Low 15.49

8EMA (Daily) 15.55	40EMA (Daily) 15.37	50EMA (Daily) 15.68	STO (Daily) 35.354	MACD Hist (Daily) -0.114
8EMA (Weekly) 15.608	40EMA (Weekly) 26.77	50EMA (Weekly) 29.26	STO (Weekly) 68.317	MACD Hist (Weekly) 1.716


Company Profile
MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company engaged in leveraging Nanobody technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases. The company focuses on developing its novel tri-specific Nanobody Sonelokimab (SLK), an IL-17A and IL-17F inhibitor, in multiple inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.